Table 1.

Proportions of BALB/c mice with relapse 3 months post-treatment.

Duration of treatment	Proportion of mice with detectable bacilli in the lungs
2HRZ/4HR	2HRZT/4HRT	2HRT/4HR
4 months (M4 + 3)	2/10	3/10	8/10
5 months (M5 + 3)	0/10	0/10	2/10
6 months (M6 + 3)	0/10	0/10	0/10

H: isoniazid at 25 mg/kg/day; R: rifampin at 10 mg/kg/day; Z: pyrazinamide at 150 mg/kg/day; T: tofacitinib at 30 mg/kg/day; and + 3: plus three months without treatment.

The columns slow the three treatment groups of BALB/c mice evaluated in this study. After receiving treatment for 4, 5, or 6 months, groups of ten mice were removed from treatment and held for 3 additional months. Following 3 months of no treatment, these mice were sacrificed and the lung homogenates subjected to CFU counting. The numbers of mice with relapse (with any detectable lung CFU) are shown.